News blog

Futura Medical

  • BY: Andrew Hore |
  • POSTED: 14/10/2015 |

Futura Medical has signed a licensing agreement with Quantum Pharma for its MED2002 erectile dysfunction treatment.

The deal will mean that MED2002 will become available as an unlicensed medicine or special, which are prescribed on a named patient basis. Quantum has the rights to manufacture and supply MED2002 in the UK and Futura will receive royalty payments.

The treatment is aimed at the 7.5% of erectile dysfunction sufferers who can’t use treatments such as Viagra.

Study results for an efficacy study should be reported by the summer of 2016. This will be followed by a second trial. In Europe the patent lasts until August 2025 and an additional three years in the US.

John Clarke is chairman of Futura and Quantum.

Futura has £7.23m in the bank at the end of June 2015, after a cash outflow of £2.26m in the previous six months. Revenues have been minimal. 

At 26p a share, up 1.75p, Futura is valued at £26m.

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds